» Authors » Sylvia E Le Devedec

Sylvia E Le Devedec

Explore the profile of Sylvia E Le Devedec including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 50
Citations 943
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Wijaya L, Kunnen S, Trairatphisan P, Fisher C, Crosby M, Schaefer K, et al.
Cell Biol Toxicol . 2025 Feb; 41(1):49. PMID: 39982567
Nephrotoxicity caused by drug or chemical exposure involves complex mechanisms as well as a temporal integration of injury and repair responses in different nephron segments. Distinct cellular transcriptional programs regulate...
2.
Piergiovanni M, Mennecozzi M, Barale-Thomas E, Danovi D, Dunst S, Egan D, et al.
Arch Toxicol . 2025 Feb; PMID: 39945818
Imaging technologies are being increasingly used in biomedical research and experimental toxicology to gather morphological and functional information from cellular models. There is a concrete opportunity of incorporating imaging-based in...
3.
Huang X, Ali A, Yachioui D, Le Devedec S, Hankemeier T
Prog Lipid Res . 2025 Feb; 98:101330. PMID: 39914749
Triple negative breast cancer (TNBC) has the worst prognosis among breast cancers due to its aggressive nature and the absence of targeted treatments. Development of novel anti-cancer drugs for TNBC...
4.
Huang X, Di X, Zuiderwijk M, Zhang L, Leegwater H, Davidse S, et al.
Talanta . 2024 Nov; 283:127127. PMID: 39520925
Lipid metabolism is essential at all stages of cancer progression, particularly for triple-negative breast cancer (TNBC) the deadliest cancer subtype for women patients. TNBC cells exhibit significant metabolic heterogeneity, which...
5.
Abyar S, Huang L, Husiev Y, Bretin L, Chau B, Ramu V, et al.
J Med Chem . 2024 Jun; 67(13):11086-11102. PMID: 38924492
Photoactivated chemotherapy agents form a new branch of physically targeted anticancer agents with potentially lower systemic side effects for patients. On the other hand, limited information exists on the intracellular...
6.
Yin J, Forn-Cuni G, Surendran A, Lopes-Bastos B, Pouliopoulou N, Jager M, et al.
Angiogenesis . 2024 Jun; 27(4):703-717. PMID: 38842752
Conjunctival melanoma (CoM) is a rare but potentially lethal cancer of the eye, with limited therapeutic option for metastases. A better understanding how primary CoM disseminate to form metastases is...
7.
Ramu V, Wijaya L, Beztsinna N, Van de Griend C, van de Water B, Bonnet S, et al.
Chem Commun (Camb) . 2024 May; 60(49):6308-6311. PMID: 38818705
The famous ''light-switch'' ruthenium complex [Ru(bpy)(dppz)](PF) (1) has been long known for its DNA binding properties . However, the biological utility of this compound has been hampered by its poor...
8.
Bretin L, Husiev Y, Ramu V, Zhang L, Hakkennes M, Abyar S, et al.
Angew Chem Int Ed Engl . 2023 Dec; 63(5):e202316425. PMID: 38061013
Photoactivated chemotherapy (PACT) is a promising cancer treatment modality that kills cancer cells via photochemical uncaging of a cytotoxic drug. Most ruthenium-based photocages used for PACT are activated with blue...
9.
Wijaya L, Gabor A, Pot I, van de Have L, Saez-Rodriguez J, Stevens J, et al.
Toxicol Sci . 2023 Nov; 198(1):14-30. PMID: 38015832
Drug-induced liver injury (DILI) remains the main reason for drug development attritions largely due to poor mechanistic understanding. Toxicogenomic to interrogate the mechanism of DILI has been broadly performed. Gene...
10.
Beerkens B, Snijders I, Snoeck J, Liu R, Tool A, Le Devedec S, et al.
J Med Chem . 2023 Aug; 66(16):11399-11413. PMID: 37531576
The adenosine A receptor (AAR) is a G protein-coupled receptor (GPCR) that exerts immunomodulatory effects in pathophysiological conditions such as inflammation and cancer. Thus far, studies toward the downstream effects...